EU debates pharmaceutical balance amid public health and industry concerns
MEPs highlighted the conflict between profit-driven private sector objectives and public health needs during discussions at the EU News Health Summit in Brussels.
MEPs are urging a reassessment of EU pharmaceutical policies to better align public health priorities with industry objectives for improved access to medicines.
Ongoing conversations will continue at the EU News Health Summit in Brussels, addressing the balance between public health and the pharmaceutical industry.
Briefing summary
This week, the EU News Health Summit in Brussels highlighted the ongoing challenges in Europe’s pharmaceutical landscape. Discussions focused on balancing public health priorities with industry competitiveness.
Tilly Metz, representing The Greens/European Free Alliance, expressed concerns regarding the alignment of private sector goals with public health needs, warning of potential negative impacts on access to medicines.
In contrast, Stine Bosse from the Renew Europe group emphasised the necessity of a robust pharmaceutical industry, suggesting that a decline could jeopardise Europe’s position in a competitive global market.
Europe’s healthcare – A right or a business model? MEPs face off in The Ring
Published on
Did you know that the price of a pill and the waiting time for a prescription vary in all EU countries?
This week on The Ring, our weekly debating show, we zoomed in on the important topic and the growing struggles in Europe’s pharmaceutical landscape. Broadcasting from EU News Health Summit in the centre of Brussels, we looked at how the EU can get the balance right between public health priorities and industry competitiveness. MEPs Tilly Metz from The Greens/European Free Alliance and Stine Bosse from the liberal Renew Europe group joined The Ring.
Tilly Metz underscored a key concern, noting that “the private sector’s objectives are not necessarily aligned with public health needs.” Her remarks highlight fears that profit-driven models may not always serve broader societal interests, especially when it comes to access to medicines and long-term health outcomes.
On the other side of the coin, Stine Bosse stressed the importance of maintaining a strong pharma industry in Europe. She cautioned that losing ground in this sector could mirror Europe’s decline in the digital industry, asking whether the continent risks looking back in a decade and seeing pharmaceuticals as “history.”